Literature DB >> 21308557

The role of second-generation antifungal triazoles for treatment of the endemic mycoses.

Alison G Freifeld1, J Ryan Bariola, David Andes.   

Abstract

Endemic fungi are geographically restricted to certain areas of the United States where they are typically found in soil. They often cause asymptomatic or self-limited flu-like infections in humans. Occasionally, they cause serious human disease including acute or chronic pneumonias, or bone, skin, or central nervous system disease. Amphotericin B and first-generation triazoles are standard therapy for serious endemic fungal infections. Adverse effects, drug intolerance, and rare refractory infections may limit their use; therefore, experience is increasing using newer triazoles (voriconazole and posaconazole) to potentially circumvent these problems. This article reviews the basic scientific information and clinical experience using triazoles for treating endemic fungal infections.

Entities:  

Year:  2010        PMID: 21308557     DOI: 10.1007/s11908-010-0133-0

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  57 in total

Review 1.  [Antimycotic drugs under continuous renal replacement therapy].

Authors:  Elke Muhl
Journal:  Mycoses       Date:  2005       Impact factor: 4.377

2.  Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.

Authors:  L Joseph Wheat; Patricia Connolly; Melinda Smedema; Michelle Durkin; Edward Brizendine; Paul Mann; Reena Patel; Paul M McNicholas; Mitchell Goldman
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

3.  Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  P G Pappas; R W Bradsher; C A Kauffman; G A Cloud; C J Thomas; G D Campbell; S W Chapman; C Newman; W E Dismukes
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

4.  Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen.

Authors:  J M Poirier; S Hardy; F Isnard; P Tilleul; J Weissenburger; G Cheymol
Journal:  Ther Drug Monit       Date:  1997-10       Impact factor: 3.681

5.  A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole.

Authors:  B Clark; R Foster; A Tunbridge; S Green
Journal:  J Infect       Date:  2005-10       Impact factor: 6.072

Review 6.  Oral azole drugs as systemic antifungal therapy.

Authors:  J A Como; W E Dismukes
Journal:  N Engl J Med       Date:  1994-01-27       Impact factor: 91.245

7.  Fluconazole-induced congenital anomalies in three infants.

Authors:  T J Pursley; I K Blomquist; J Abraham; H F Andersen; J A Bartley
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 8.  Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity.

Authors:  M O Gearhart
Journal:  Ann Pharmacother       Date:  1994-10       Impact factor: 3.154

9.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.

Authors:  Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

Review 10.  Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.

Authors:  Roger J M Brüggemann; Jan-Willem C Alffenaar; Nicole M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David M Burger
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079

View more
  1 in total

Review 1.  Successful treatment of osseous blastomycosis without pulmonary or disseminated disease and review of the literature.

Authors:  Shandra R Day; David B Weiss; Kevin C Hazen; Christopher C Moore
Journal:  Diagn Microbiol Infect Dis       Date:  2014-03-07       Impact factor: 2.803

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.